Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: A systematic comparison

European Journal of Haematology

Volumn 79, Issue 2, 2007, Pages 93-99

  Prince, H Miles ^a,b   Adena, Michael ^c   Smith, Dell Kingsford ^c,d   Hertel, Judy ^d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Pty Ltd   (Australia)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Bortezomib; Multiple myeloma; Refractory; Relapsed; Thalidomide

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; M PROTEIN; THALIDOMIDE;

AGE; COCHRANE LIBRARY; COMPARATIVE STUDY; DISEASE DURATION; DRUG EFFICACY; EMBASE; GENDER; HUMAN; MEDLINE; MONOTHERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANIMALS; BLOOD PROTEINS; BORONIC ACIDS; CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; THALIDOMIDE;

EID: 34447303363     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00886.x     Document Type: Review

References (38)

1. San-Miguel J, Blade J. Perspective on the current use of bortezomib in multiple myeloma. Haematologica 2006 91 : 871 2.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999 341 : 1565 71.
3. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, Yu Z, Olesnyckyj M, Zeldis J, Knight R. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]. Blood 2005 106 : 6a 7a.
4. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001 28 : 613 9.
5. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001 61 : 3071 6.
6. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003 101 : 1530 4.
7. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002 62 : 4996 5000.
8. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003 101 : 2377 80.
9. Ribas C, Colleoni GW. Advances in the treatment of multiple myeloma: the role of thalidomide. Leuk Lymphoma 2003 44 : 291 8.
10. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006 106 : 1316 9.
11. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004 127 : 165 72.
12. Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, Kienast J. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005 29 : 587 90.
13. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001 12 : 991 5.
14. Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004 5 : 318 24.
15. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003 121 : 768 71.
16. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003 21 : 16 19.
17. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschluter M. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006 132 : 584 93.
18. Prince HM, Mileshkin L, Schenkel B. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007 48 : 46 55.
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998 102 : 1115 23.
20. derSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 88.
21. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005 352 : 2487 98.
22. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002 3 : 185 92.
23. Grosbois B, Bellisant E, Moreau P, Attal M, Zerbib R. Thalidomide in the treatment of advanced multiple myeloma. A prospective study of 120 patients. Blood 2001 98 : 163a.
24. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006 20 : 1467 73.
25. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001 98 : 492 4.
26. Grosbois B, Moreau E, Attal P, Zerbib M. Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. Blood 2001 98 : 163a.
27. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002 8 : 3377 82.
28. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003 102 : 69 77.
29. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003 27 : 909 14.
30. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002 87 : 408 14.
31. Waage A, Gimsing P, Juliusson G, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004 125 : 149 55.
32. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, Hellmann A, Wolska-Smolen T, Skotnicki A, Manko J. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001 86 : 404 8.
33. Alexanian RWD. Thalidomide for resistant and relapsing myeloma. Semin Hematol 2000 37 : 22 25.
34. Hattori Y, Kakimoto T, Okamoto S, Sato N, Ikeda Y. Thalidomide-induced severe neutropenia during treatment of multiple myeloma. Int J Hematol 2004 79 : 283 8.
35. Cibeira MT, Esteve J, Torrebadell M, Arenillas L, Blade J, Montserrat E. Thalidomide in refractory and relapsed multiple myeloma: duration of response 10th International Workshop on Multiple Myeloma. Sydney, Australia. Haematologica, 2005 : 140.
36. Offidani M, Corvatta L, Marconi M, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004 72 : 403 9.
37. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003 78 : 34 39.
38. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004 79 : 875 82.